EUCTR2006-001637-18-IT进行中（未招募）不适用
A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy - PROTECT-2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Oral loop diuretic prescribed as daily heart failure therapy for at least 14 days prior to hospital admission. Hospitalized for AHFS requiring IV diuretic therapy, age >18, JVP >8cm, Creatinine clearance >20mL/min <80mL/min, systolic blood pressure >95mmHg
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Ongoing or planned IV therapy with positive inotropic agents, vasopressor,vasodilators or mechanical support. pregnant or breast feeding women. temperature>38?C, BNP<250pg/ml, systolic blood pressure >160mmHg, History of seizure, Heart transplant
研究者
相似试验
进行中（未招募）
1 期
A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy - Protect-1 (CKI-301)Subjects who are hospitalized with AHFS, volume overload, who require IV diuretic therapyMedDRA version: 9.1 Level: HLGT Classification code 10007539 Term: Cardiac disorder signs and symptomsEUCTR2007-001407-37-ITovaCardia Inc.600
进行中（未招募）
1 期
Dose-finding study to evaluate efficacy and safety of LOU064 in patients with CSU inadequately controlled by H1-antihistaminesChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-000993-31-DKovartis Pharma AG308
已完成
3 期
A multicenter, randomized, double-blind, placebo- controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patientsAcute Heartfailure10019280NL-OMON45125ovartis125
进行中（未招募）
1 期
Dose-finding study to evaluate efficacy and safety of LOU064 in patients with CSU inadequately controlled by H1-antihistaminesChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-000993-31-CZovartis Pharma AG308
进行中（未招募）
1 期
Dose-finding study to evaluate efficacy and safety of LOU064 in patients with CSU inadequately controlled by H1-antihistaminesChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-000993-31-SKovartis Pharma AG308